Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasserman, Matt, Palacios, Maria Gabriela, Grajales, Ana Gabriela, Wilson, Michele, McDade, Cheryl, Farkouh, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Reply Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988870/
https://www.ncbi.nlm.nih.gov/pubmed/30657407
http://dx.doi.org/10.1080/21645515.2018.1558691
Descripción
Sumario:In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional information and clarifies potential misinterpretations.

Ejemplares similares